As a matter of fact, we have recently witnessed the approval of several ICIs according to PD-L1 expression in different malignancies, as in the case of the PD-1 inhibitor pembrolizumab in previously untreated patients with advanced non-small cell lung cancer (NSCLC) with PD-L1 Tumor Proportion Score (TPS) of 50% or more (31–33). This evidence concerns the gene CD274 and non-small cell lung carcinoma.